Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Jain

Showing results (401-410 of 420) with videos related to

Pageof 42
Sort By:
Blood Advances|April 8, 2025
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucelSatabdi Saha, Lubna Rehman, Abdur Rehman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2024
Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical TrialChandrasekaran Padmapriyadarsini, Vikas S Oswal, Chetankumar D Jain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T ConsortiumYucai Wang, Preetesh Jain, Frederick L Locke, et al.
Blood Cancer Journal|August 26, 2025
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphomaMichael Winkelmann, Sandeep S Raj, Michael D Jain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumMichael D Jain, Jay Y Spiegel, Loretta J Nastoupil, et al.
Transplantation and Cellular Therapy|October 9, 2025
Erratum to <Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome><[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>Melissa R Hines, Tristan E Knight, Kevin O McNerney, et al.
Transplantation and Cellular Therapy|March 11, 2023
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeMelissa R Hines, Tristan E Knight, Kevin O McNerney, et al.
Bone Marrow Transplantation|March 2, 2025
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative studyMohamed A Kharfan-Dabaja, Razan Mohty, Neela Easwar, et al.
Blood Cancer Discovery|January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell LymphomaRawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Blood Advances|August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myelomaJennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Pageof 42

Showing results (401-410 of 420) with videos related to

Sort By:
Pageof 42
Blood Advances|April 8, 2025
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucelSatabdi Saha, Lubna Rehman, Abdur Rehman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2024
Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical TrialChandrasekaran Padmapriyadarsini, Vikas S Oswal, Chetankumar D Jain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T ConsortiumYucai Wang, Preetesh Jain, Frederick L Locke, et al.
Blood Cancer Journal|August 26, 2025
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphomaMichael Winkelmann, Sandeep S Raj, Michael D Jain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumMichael D Jain, Jay Y Spiegel, Loretta J Nastoupil, et al.
Transplantation and Cellular Therapy|October 9, 2025
Erratum to <Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome><[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>Melissa R Hines, Tristan E Knight, Kevin O McNerney, et al.
Transplantation and Cellular Therapy|March 11, 2023
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeMelissa R Hines, Tristan E Knight, Kevin O McNerney, et al.
Bone Marrow Transplantation|March 2, 2025
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative studyMohamed A Kharfan-Dabaja, Razan Mohty, Neela Easwar, et al.
Blood Cancer Discovery|January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell LymphomaRawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Blood Advances|August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myelomaJennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Pageof 42